本帖最后由 老马 于 2012-1-13 21:20 编辑 : c. g8 K4 ?' u+ l
! g9 s1 j/ C& T0 x$ ?) r爱必妥和阿瓦斯丁的比较1 s$ R0 c# ?5 z# W
7 a( g" q3 H& I8 A) Chttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/1 I' s7 F, F# T& C* V
3 i x0 Z6 J1 n5 F( f6 H
5 r' C; A" P' X8 ^http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
0 J- z: T& D+ j: D4 v# T& `==================================================7 _" T: ~* m; S& `+ I
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2 e! A# Q/ N9 S( r3 `7 r% K( ?Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.6 r9 i9 O5 G5 f4 H# J7 j! u" [8 ?
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.0 o1 e- U/ o- a0 z4 d! s3 d
|